



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/020,541	04/26/2002	Larry A. Wheeler	17400(BAR)	1687
7590	01/06/2009		EXAMINER	
Carlos A. Fisher ALLERGAN, INC. T2-7H 2525 Dupont Drive Irvine, CA 92612			ANGELL, JON E	
			ART UNIT	PAPER NUMBER
			1635	
			MAIL DATE	DELIVERY MODE
			01/06/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/020,541	Applicant(s) WHEELER ET AL.
	Examiner J. E. Angell	Art Unit 1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 08 February 2008.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 16,18-22,30,39 and 40 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) 16,18-22,30,39 and 40 is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/06)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

This Action is in response to the communication filed on 2/8/2008.

The amendment filed 2/8/2008 is acknowledged and has been entered.

Applicant's arguments are addressed on a per section basis. The text of those sections of Title 35, U.S. Code not included in this Action can be found in a prior Office Action. Any rejections not reiterated in this action have been withdrawn as being obviated by the amendment of the claims and/or applicant's arguments.

Claims 16, 18-22, 30, 39, 40 are currently pending in the application and are addressed herein.

Priority

Per the 10/27/2008 Decision of the Petition for Reinstatement of the Priority Date, the filing date of the Application is April 26, 2002.

Claim Rejections - 35 USC § 103

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 16, 18-22, 30, 39, 40 are rejected under 35 U.S.C. 103(a) as being obvious over U.S. Patent 6,456,464 (Wheeler, previously of record) in view of U.S. Patent 5,910,510 (Strong) and U.S. Patent Application Publication US 2002/0040015 A1 (Miller et al.; previously of record).

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention “by another”; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). This rejection might also be overcome by showing that the reference is disqualified under 35 U.S.C. 103(c) as prior art in a rejection under 35 U.S.C. 103(a). See MPEP § 706.02(l)(1) and § 706.02(l)(2).

Wheeler et al. discloses and claims a method of providing neural protection including glaucomatous optic neuropathy to a mammal comprising administering to the mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of brimonidine to inhibit or prevent nerve cell injury or death (claim 1, column 17); wherein the noxious action is a laser light directed into the eye in a procedure for treatment of wet age-related macular degeneration (ARMD) (claim 7, column 18); administering an amount sufficient to achieve a serum concentration of from 0.01 nM to 500 nM (claim 15, column 18) or the compound is administered topically (claim 16, column 18). See also, claim 5.

Laser light directed noxious action for treatment of wet ARMD is disclosed in the specification as the photodynamic therapy (PDT) treatment of wet (neovascular) ARMD, wherein a photosensitive dye is given systemically to a patient, which is taken up only in abnormal tissues such as the abnormal vessels present in wet ARMD. A "cold" laser is directed into the eye, which activates the dye taken up in the cell walls of the abnormal vessels, thus forming oxidative compounds that lead to clot formation in the neovascular tissues. Since the laser treatment can cause photic damage to the retina, the compounds are to be administered to protect the retina from damage by the laser light used as a part of this ARMD therapy. Column 5, line 63-column 6, line 13. The method of administering the compound to the mammal is either systemically, topically, intrathecally, epidurally or by intrabulbar injection of an effective amount of the aryl-imino-2-imidazolidines including brimonidine. Column 6, lines 30-38. More preferably, the compounds are administered directly into the eye, either topically or through injection into the eye. Column 7, lines 10-15.

For acute neuroprotective effect such as photoprotection in the laser treatment for ARMD, the protective agent would be administered in advance of the treatment to provide optimal protection during the laser procedure. Column 7, lines 62-66.

Figure 5 exemplifies brimonidine in topical neuroprotection in a dose dependent manner. Column 9, line 55-65, and Figure 5.

Wheeler also teaches that the neuroprotective agent should be administered in a dose to achieve a serum or intravitreal concentration of 0.01 nM to 500 mM. Preferably the

Art Unit: 1635

neuroprotective agent is administered prior to injury to the nerve, but can be administered after injury has occurred to lessen the effect. Column 12, lines 34-53.

Wheeler does not teach using an electromagnetic radiation intensity in the range of 150-900 mW/cm², as is required by the claims. In fact, it does not appear that Wheeler teaches using any specific radiation intensity.

Wheeler also does not teach that the method also comprises a therapeutically effective amount of an antiangiogenic compound.

Strong teaches using photodynamic therapy is useful for treating conditions of the eye, including conditions characterized by unwanted neovascular and specifically teaches that an electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use, with between about 150-600 mW/cm² being a preferred intensity (e.g., see abstract, paragraph bridging columns 4 and 5, etc.).

Miller teaches a method and composition for treating conditions of the eye. Specifically, Miller teaches a method for photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature which includes enhancing the PDT method by administering an antiangiogenic compound (e.g., see abstract; paragraph 18; claims 20-31, etc.). It is noted that the instant specification acknowledges it was previously known that PDT can result in optic nerve atrophy (See p. 3, first paragraph). It is noted that the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000.

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use the method taught by Wheeler with the electromagnetic

Art Unit: 1635

radiation intensity taught by Strong to create the claimed method with a reasonable expectation of success.

The motivation to combine the references to create claimed invention is provided by Strong, who teaches that electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use in photodynamic therapy.

It would have been further *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings Miller with the other reference to create the claimed method wherein an antiangiogenic compound is used in combination with a reasonable expectation of success.

The motivation to combine the references to create claimed invention is provided by Miller who teaches using an antiangiogenic compound in combination with PDT.

3. Claims 16, 18-22, 30, 39, 40 rejected under 35 U.S.C. 103(a) as being obvious over U.S. Patent 6,194,415 (Wheeler, previously of record) in view of U.S. Patent 5,910,510 (Strong) and U.S. Patent Application Publication US 2002/0040015 A1 (Miller et al.; previously of record).

The applied reference has a common Inventor with the instant application.

However, the reference additionally qualifies as prior art under another subsection of 35 U.S.C. 102, and therefore, can not be disqualified as prior art under 35 U.S.C. 103(c).

Applicant may overcome the applied art either by a showing under 37 CFR 1.132 that the invention disclosed therein was derived from the invention of this application, and is therefore, not the invention "by another," or by antedating the applied art under 37 CFR 1.131.

Claim 1 of '415 is drawn to a method of protecting the optic nerve and retina of a mammal comprising administering to the mammal suffering from or at risk of suffering a noxious action on the nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death, wherein the formula encompass brimonidine, and wherein the noxious action includes laser light directed into the eye in a procedure for treatment of wet ARMD. Claim 4 depends from claim 1 and recites that the noxious action is laser light directed into the eye in a procedure for treatment of wet ARMD.

The supporting disclosure to understand the treatment of wet ARMD in the '415 patent claims is the same as for the claims of US 6,465,464 set forth above, since the application that issued as '415 is the continuation parent of the application that issued as '464. However, claims 1 and 4 of '415 recite the method using a generic compound of formula I that encompass brimonidine. Furthermore, Figure 5 exemplifies brimonidine in topical neuroprotection in a dose dependent manner. Column 9, line 55-65, and Figure 5.

Wheeler does not teach using an electromagnetic radiation intensity in the range of 150-900 mW/cm², as is required by the claims. In fact, it does not appear that Wheeler teaches using any specific radiation intensity.

Wheeler also does not teach does not teach that the method also comprises a therapeutically effective amount of an antiangiogenic compound.

Strong teaches using photodynamic therapy is useful for treating conditions of the eye, including conditions characterized by unwanted neovascular and specifically teaches that an electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to

Art Unit: 1635

use, with between about 150-600 mW/cm² being a preferred intensity (e.g., see abstract, paragraph bridging columns 4 and 5, etc.).

Miller teaches a method and composition for treating conditions of the eye. Specifically, Miller teaches a method for photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature which includes enhancing the PDT method by administering an antiangiogenic compound (e.g., see abstract; paragraph 18; claims 20-31, etc.). It is noted that the instant specification acknowledges it was previously known that PDT can result in optic nerve atrophy (See p. 3, first paragraph). It is noted that the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000.

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use the method taught by Wheeler with the electromagnetic radiation intensity taught by Strong to create the claimed method with a reasonable expectation of success.

The motivation to combine the references to create claimed invention is provided by Strong, who teaches that electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use in photodynamic therapy.

It would have been further *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings Miller with the other reference to create the claimed method wherein an antiangiogenic compound is used in combination with a reasonable expectation of success.

4. Claims 16, 18-22, 30, 39, 40 rejected under 35 U.S.C. 103(a) as being obvious over U.S. Patent 6,248,741 B1 (Wheeler, previously of record) in view of U.S. Patent 5,910,510 (Strong) and U.S. Patent Application Publication US 2002/0040015 A1 (Miller et al.; previously of record).

The applied reference has a common Inventor with the instant application.

However, the reference additionally qualifies as prior art under another subsection of 35 U.S.C. 102, and therefore, can not be disqualified as prior art under 35 U.S.C. 103(c).

Applicant may overcome the applied art either by a showing under 37 CFR 1.132 that the invention disclosed therein was derived from the invention of this application, and is therefore, not the invention "by another," or by antedating the applied art under 37 CFR 1.131.\

The disclosure of the '741 patent appears to be the same as that of the '415 and '464 patents. It is noted that the claims of the '741 patent are very similar, but narrower in scope than the claims of the '415 patent. Claim 1 of '741 is drawn to a method of protecting the optic nerve and retina of a mammal comprising administering to the mammal suffering from or at risk of suffering a noxious action on the nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death, wherein the formula encompass brimonidine, and wherein the noxious action includes laser light directed into the eye in a procedure for treatment of wet ARMD. Claim 7 depends from claim 1 and recites that the noxious action is laser light directed into the eye in a procedure for treatment of wet ARMD. Furthermore, Figure 5 exemplifies brimonidine in topical neuroprotection in a dose dependent manner. Column 9, line 55-65, and Figure 5.

Wheeler does not teach using an electromagnetic radiation intensity in the range of 150-900 mW/cm², as is required by the claims. In fact, it does not appear that Wheeler teaches using any specific radiation intensity.

Wheeler also does not teach that the method also comprises a therapeutically effective amount of an antiangiogenic compound.

Strong teaches using photodynamic therapy is useful for treating conditions of the eye, including conditions characterized by unwanted neovascular and specifically teaches that an electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use, with between about 150-600 mW/cm² being a preferred intensity (e.g., see abstract, paragraph bridging columns 4 and 5, etc.).

Miller teaches a method and composition for treating conditions of the eye. Specifically, Miller teaches a method for photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature which includes enhancing the PDT method by administering an antiangiogenic compound (e.g., see abstract; paragraph 18; claims 20-31, etc.). It is noted that the instant specification acknowledges it was previously known that PDT can result in optic nerve atrophy (See p. 3, first paragraph). It is noted that the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000.

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use the method taught by Wheeler with the electromagnetic radiation intensity taught by Strong to create the claimed method with a reasonable expectation of success.

The motivation to combine the references to create claimed invention is provided by Strong, who teaches that electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use in photodynamic therapy.

It would have been further *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings Miller with the other reference to create the claimed method wherein an antiangiogenic compound is used in combination with a reasonable expectation of success.

The motivation to combine the references to create claimed invention is provided by Miller who teaches using an antiangiogenic compound in combination with PDT.

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1635

2. Claims 16, 18-22, 30, 39 and 40 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 6,194,415 in view of Wheeler et al. (Euro. J. Ophthalm., 1999; previously of record), and further in view of U.S. Patent Application publication No US 2002/0040015 A1 (Miller et al.; previously of record) and U.S. Patent 5,910,510 (Strong).

3. The claims of '415 are drawn to a method of protecting the optic nerve and retina of a mammal comprising administering to the mammal suffering from or at risk of suffering a noxious action on the nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death, wherein the formula encompass brimonidine, and wherein the noxious action includes laser light directed into the eye in a procedure for treatment of wet ARMD. Claim 4 depends from claim 1 and recites that the noxious action is laser light directed into the eye in a procedure for treatment of wet ARMD.

4. The patent does not claim that the method comprises administering brimonidine as the compound of formula I or a therapeutically effective amount of an antiangiogenic compound or using an electromagnetic radiation intensity in the range of 150-900 mW/cm².

However, Wheeler et al (1999) teaches brimonidine as a neuroprotective agent.

Intraperitoneal brimonidine enhanced rat retinal ganglion cell survival and function in the partial crush injury model, and shown that the neuroprotection was dose-dependent. Topical application of brimonidine 1 hour before injury was effective in decreasing ischemic retinal injury. Ischemic retinas treated with brimonidine resulted with a large decrease in TUNEL staining. See the abstract on page S17, METHODS on pages S18-S19 and RESULTS and DISCUSSION on pages S20-S21.

Miller teaches a method and composition for treating conditions of the eye. Specifically, Miller teaches a method for photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature which includes enhancing the PDT method by administering an antiangiogenic compound (e.g., see abstract; paragraph 18; claims 20-31, etc.). It is noted that the instant specification acknowledges it was previously known that PDT can result in optic nerve atrophy (See p. 3, first paragraph). It is noted that the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000.

Strong teaches using photodynamic therapy is useful for treating conditions of the eye, including conditions characterized by unwanted neovascular and specifically teaches that an electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use, with between about 150-600 mW/cm² being a preferred intensity (e.g., see abstract, paragraph bridging columns 4 and 5, etc.).

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the indicated teachings to create the claimed method with a reasonable expectation of success.

Claims 16, 18-22, 39, 30 and 40 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 6,248,741 in view of Wheeler et al. (Euro. J. Ophthalm, 1999; previously of record) and further in view of U.S. Patent Application publication No US 2002/0040015 A1 (Miller et al.; previously of record) and U.S. Patent 5,910,510 (Strong).

The claims 1 of '741 is drawn to a method of protecting the optic nerve and retina of a mammal comprising administering to the mammal suffering from or at risk of suffering a noxious action on the nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death, wherein the formula encompass brimonidine, and wherein the noxious action includes laser light directed into the eye in a procedure for treatment of wet ARMD. Claim 7 depends from claim 1 and recites that the noxious action is laser light directed into the eye in a procedure for treatment of wet ARMD.

The patent does not claim that the method comprises administering brimonidine as the compound of formula I or a therapeutically effective amount of an antiangiogenic compound.

Wheeler et al (1999) teaches brimonidine as a neuroprotective agent. Intraperitoneal brimonidine enhanced rat retinal ganglion cell survival and function in the partial crush injury model, and shown that the neuroprotection was dose-dependent. Topical application of brimonidine 1 hour before injury was effective in decreasing ischemic retinal injury. Ischemic retinas treated with brimonidine resulted with a large decrease in TUNEL staining. See the abstract on page S17, METHODS on pages S18-S19 and RESULTS and DISCUSSION on pages S20-S21.

Miller teaches a method and composition for treating conditions of the eye. Specifically, Miller teaches a method for photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature which includes enhancing the PDT method by administering an antiangiogenic compound (e.g., see abstract; paragraph 18; claims 20-31, etc.). It is noted that the instant specification acknowledges it was previously known that PDT

Art Unit: 1635

can result in optic nerve atrophy (See p. 3, first paragraph). It is noted that the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000.

Strong teaches using photodynamic therapy is useful for treating conditions of the eye, including conditions characterized by unwanted neovascular and specifically teaches that an electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use, with between about 150-600 mW/cm² being a preferred intensity (e.g., see abstract, paragraph bridging columns 4 and 5, etc.).

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the indicated teachings to create the claimed method with a reasonable expectation of success.

5. Claims 16, 18-22, 30, 39 and 40 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 6,465,464 in view of Wheeler et al. (Euro. J. Ophthalm, 1999; previously of record) and further in view of U.S. Patent Application publication No US 2002/0040015 A1 (Miller et al.; previously of record) and U.S. Patent 5,910,510 (Strong).

6. As indicated above, Wheeler et al. discloses and claims a method of providing neural protection including glaucomatous optic neuropathy to a mammal comprising administering to the mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of brimonidine to inhibit or prevent nerve cell injury or death (claim 1, column 17);

wherein the noxious action is a laser light directed into the eye in a procedure for treatment of wet age-related macular degeneration (ARMD) (claim 7, column 18); administering an amount sufficient to achieve a serum concentration of from 0.01 nM to 500 nM (claim 15, column 18) or the compound is administered topically (claim 16, column 18). See also, claim 5.

7. The patent does not claim that the method comprises administering brimonidine as the compound of formula I or a therapeutically effective amount of an antiangiogenic compound.

Wheeler et al (1999) teaches brimonidine as a neuroprotective agent. Intraperitoneal brimonidine enhanced rat retinal ganglion cell survival and function in the partial crush injury model, and shown that the neuroprotection was dose-dependent. Topical application of brimonidine 1 hour before injury was effective in decreasing ischemic retinal injury. Ischemic retinas treated with brimonidine resulted with a large decrease in TUNEL staining. See the abstract on page S17, METHODS on pages S18-S19 and RESULTS and DISCUSSION on pages S20-S21.

Miller teaches a method and composition for treating conditions of the eye. Specifically, Miller teaches a method for photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature which includes enhancing the PDT method by administering an antiangiogenic compound (e.g., see abstract; paragraph 18; claims 20-31, etc.). It is noted that the instant specification acknowledges it was previously known that PDT can result in optic nerve atrophy (See p. 3, first paragraph). It is noted that the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000.

Strong teaches using photodynamic therapy is useful for treating conditions of the eye, including conditions characterized by unwanted neovascular and specifically teaches that an electromagnetic radiation intensity in the range of 150-900 mW/cm² is an effective intensity to use, with between about 150-600 mW/cm² being a preferred intensity (e.g., see abstract, paragraph bridging columns 4 and 5, etc.).

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the teachings to create the claimed method with a reasonable expectation of success.

Response to Arguments

8. Applicant's arguments filed 2/8/2008 have been fully considered but they are not persuasive.
9. Regarding the issue of Priority, Applicants arguments have been considered, but are not persuasive in view of the 10/27/2008 Decision on the Petition, which sets forth the reasons why the current Application is given a filing date of April 26, 2002.
10. With respect to the Patents that have a common inventor, Applicants argue that the Patents and the instant claimed invention were commonly owned and therefore not available as prior art under 35 U.S.C. 103(a).
11. This is not persuasive because the rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application

which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). Since Applicants arguments are not presented in one of the required Declarations, Applicants arguments are not persuasive. Furthermore, only Patents applicable as prior art only under 102(e), (f) and (g) may be overcome by the indicated Declaration(s). Patents Applicable as prior art under any other part of 102 may not be obviated by Declaration of common ownership.

12. Applicants argue that the claims require damage by a photoactive component and this is not taught by the references.

13. In response, it is respectfully pointed out that without a clear definition of "photoactive component" in the specification, the term is given its broadest reasonable interpretation. In the instant case, the electromagnetic radiation used in the method can be considered "a photoactive component" as it is the light component of the method.

14. Applicants argue that Miller is not applicable as prior art for the reasons previously submitted.

15. In response, the effective filing date of the Miller reference, with respect to PDT in combination with an anti-angiogenic agent is 2/10/2000; thus, Miller is applicable as prior art back to 2/10/2000.

16. With respect to the Double Patenting rejections, Applicants argue that the Examiner is in error as the Double Patenting rejection must be based solely on the issued claims, without any another reference.

17. This argument would be persuasive if the rejection were a Statutory Double Patenting Rejection. However, the rejections are Obvious-type Double Patenting rejections where it is acceptable to utilize more than the issued claims to show what was *prima facie* obvious.

18. Therefore, Applicants arguments are not persuasive as they pertain to the instant rejections.

Conclusion

19. No claim is allowed.

20. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. E. Angell whose telephone number is 571-272-0756. The examiner can normally be reached on Monday-Thursday 8:00 a.m.-6:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Douglas Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/J. E. Angell/
Primary Examiner, Art Unit 1635